SEC Form 4 · accession 0001470831-26-000550
BridgeBio Pharma, Inc. · BBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer E. Cook
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 4:45 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001743881
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2026 | M | 65,921 | $8.45 | A | 79,662 | D | |
| Common Stock | Jun 15, 2026 | M | 17,167 | $16.75 | A | 96,829 | D | |
| Common StockF2 | Jun 15, 2026 | S | 88,737 | $66.6153 | D | 8,092 | D | |
| Common StockF3 | Jun 15, 2026 | S | 1,503 | $67.1425 | D | 6,589 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $8.45 | Jun 15, 2026 | M | 65,921 | D | — | Jun 22, 2032 | Common Stock | 65,921 | 39,000 | D |
| Stock Option (Right to Buy)F5 | $16.75 | Jun 15, 2026 | M | 17,167 | D | — | Jun 21, 2033 | Common Stock | 17,167 | 34,334 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
- F2Represents the weighted average sale price of the shares sold from $66.10 to $67.095 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F3Represents the weighted average sale price of the shares sold from $67.10 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F41/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
- F51/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
Remarks
Exhibit 24 - Power of Attorney